stockrow
Saturday 7 November 2026
Export ATHE’s income statement to Excel — free account
Alterity Therapeutics Limited - Sponsored ADR
ATHE Healthcare Biotechnology
2.44
0.22
+9.91%
Follow ATHE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | 2 | 3 | 4 | 0 | 3 | — | — | — | — | — | +9.1% | — | — | — | — | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | (100.0) pt | ||||||
| EBT | (6) | (6) | (9) | (9) | (11) | (9) | (9) | (13) | (8) | (16) | +12.0% | ||||||
| EBT margin, % | (239.05) | (248.45) | (243.84) | (9,623.22) | (339.76) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +239.0 pt | ||||||
| Net income | (6) | (6) | (9) | (9) | (11) | (9) | (9) | (13) | (8) | (16) | +12.1% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 2.67 | 2.90 | 3.53 | 0.06 | 1.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (6.40) | (7.00) | (8.40) | (6.24) | (4.04) | (2.32) | (2.31) | (2.02) | (0.74) | (0.91) | (19.5%) | ||||||
| Cash flow | (4.97) | (5.44) | (9.72) | (4.25) | (4.58) | (2.23) | (3.33) | (1.36) | (0.70) | (0.87) | (17.6%) | ||||||
| Capex | (0.02) | (0.05) | 0.00 | (0.01) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (4.99) | (5.49) | (9.73) | (4.25) | (4.58) | (2.25) | (3.33) | (1.36) | (0.70) | (0.87) | (17.6%) | ||||||
| Book value | 20.07 | 14.01 | 11.54 | 3.22 | 8.05 | 6.42 | 3.80 | 1.49 | 2.58 | 1.65 | (24.2%) | ||||||
| Shares, m | 1 | 1 | 1 | 1 | 3 | 4 | 4 | 6 | 11 | 18 | +39.3% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.0 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.0 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.0 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.0 | ||||||
| EV/FCF | 1.06 | 1.10 | 0.49 | 0.31 | 1.73 | — | — | — | — | — | 0.9 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (4) | (5) | (10) | (6) | (13) | (9) | (13) | (8) | (7) | (15) | +14.8% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | (21.7%) | ||||||
| Free cash flow | (4) | (5) | (10) | (6) | (13) | (9) | (13) | (8) | (7) | (15) | +14.7% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 18 | 12 | 12 | 5 | 23 | 26 | 15 | 9 | 27 | 29 | +5.5% | |||||
| Net debt | (16) | (12) | (10) | (6) | (21) | (25) | (11) | (8) | (21) | (25) | +4.9% | ||||||
| Shareholders’ equity | 18 | 12 | 12 | 5 | 23 | 26 | 15 | 9 | 27 | 29 | +5.5% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (26.06) | (38.17) | (61.37) | (86.50) | (72.06) | (33.83) | (38.41) | (80.92) | (37.10) | (52.04) | (26.0) pt | |||||
| ROIC | (229.92) | (574.31) | (358.62) | 0.00 | (396.76) | (1,656.09) | (154.05) | (1,248.22) | (135.49) | (327.72) | (97.8) pt | ||||||
| ROE | (27.93) | (42.26) | (72.60) | (108.60) | (82.99) | (38.44) | (45.24) | (102.77) | (43.10) | (56.26) | (28.3) pt | ||||||
| People | |||||||||||||||||
| People | Employees | 9 | 14 | 14 | 12 | 11 | 12 | 12 | 10 | 9 | 9 | 0.0% | |||||
| Revenue/emp, $m | 0.26 | 0.18 | 0.26 | 0.01 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2021
Alterity Therapeutics Limited - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | $44.4M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $44.2M | — (loss-making) | — (loss-making) | −26.89% (below 0%: shrinking) | n/m | +84.78% (above 0%: growing) | 100.00% | (1,720.10%) | Compare |
| BMEA Biomea Fusion, Inc. | $42.6M | — (loss-making) | — | — | n/m | +47.80% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $42.4M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | |
| GANX Gain Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SER Serina Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SGMOQ Sangamo Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | −77.60% (below 0%: shrinking) | n/m | +26.21% (above 0%: growing) | 100.00% | (2,215.40%) | Compare |
| LONA LeonaBio, Inc. | $40.9M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $40.9M | 3.9× | 8.4× | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| Median of peers | $41.9M | — | — | +63.89% | — | +1.66% | 100.00% | 0.00% |